Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

Am J Respir Crit Care Med. 2019 May 1;199(9):1167-1168. doi: 10.1164/rccm.201812-2281LE.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antitubercular Agents
  • Humans
  • Rifampin*
  • Tuberculosis, Pulmonary*

Substances

  • Antitubercular Agents
  • Rifampin